- Home
- ACXP vs PMAX Comparison
ACXP vs PMAX Comparison
Compare ACXP & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- PMAX
- Stock Information
- Founded
- ACXP 2017
- PMAX 2019
- Country
- ACXP United States
- PMAX Hong Kong
- Employees
- ACXP N/A
- PMAX N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- PMAX
- Sector
- ACXP Health Care
- PMAX
- Exchange
- ACXP Nasdaq
- PMAX Nasdaq
- Market Cap
- ACXP 6.8M
- PMAX 6.7M
- IPO Year
- ACXP 2021
- PMAX 2024
- Fundamental
- Price
- ACXP $4.23
- PMAX $0.29
- Analyst Decision
- ACXP Strong Buy
- PMAX
- Analyst Count
- ACXP 3
- PMAX 0
- Target Price
- ACXP $143.67
- PMAX N/A
- AVG Volume (30 Days)
- ACXP 68.2K
- PMAX 2.1M
- Earning Date
- ACXP 11-12-2025
- PMAX 10-17-2025
- Dividend Yield
- ACXP N/A
- PMAX N/A
- EPS Growth
- ACXP N/A
- PMAX N/A
- EPS
- ACXP N/A
- PMAX N/A
- Revenue
- ACXP N/A
- PMAX $4,694,079.00
- Revenue This Year
- ACXP N/A
- PMAX N/A
- Revenue Next Year
- ACXP N/A
- PMAX N/A
- P/E Ratio
- ACXP N/A
- PMAX N/A
- Revenue Growth
- ACXP N/A
- PMAX N/A
- 52 Week Low
- ACXP $3.80
- PMAX $0.23
- 52 Week High
- ACXP $44.00
- PMAX $4.60
- Technical
- Relative Strength Index (RSI)
- ACXP 48.38
- PMAX 42.68
- Support Level
- ACXP N/A
- PMAX $0.29
- Resistance Level
- ACXP $4.34
- PMAX $0.33
- Average True Range (ATR)
- ACXP 0.45
- PMAX 0.04
- MACD
- ACXP -0.05
- PMAX 0.00
- Stochastic Oscillator
- ACXP 59.16
- PMAX 26.73
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.